Cure8 news brief
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials confirm efficacy and safety.
Adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis, patients on or considering biologic therapies, IBD clinicians, and researchers interested in targeted IBD drug development.
Nature Reviews reports positive phase IIb results for duvakitug, an anti‑TL1A monoclonal antibody tested in the RELIEVE UCCD programme, which ran parallel randomized, placebo‑controlled trials in moderate‑to‑severe Crohn’s disease and ulcerative colitis.
Doses of 450 mg and 900 mg were evaluated versus placebo over 14 weeks; endoscopic response and clinical remission at week 14 favored duvakitug, and no major safety signals were identified in these trials. These are phase IIb dose‑ranging results reported in a review article summarizing Lancet Gastroenterology & Hepatology publications.
The review notes numerically higher response/remission rates with the 900 mg dose compared with 450 mg and placebo, and states that larger phase III trials have been initiated.
If you are reading this because you or someone you care for has IBD, this is early but encouraging drug‑development news: it shows a new targeted monoclonal antibody (anti‑TL1A) can have measurable benefit in both Crohn’s disease and ulcerative colitis in controlled phase IIb testing.
It is not a treatment recommendation; access, approval, and long‑term safety remain to be established in phase III and regulatory review.
These results come from phase IIb randomized trials summarized in a Nature Reviews article citing Lancet Gastroenterology & Hepatology publications. Phase III trials have been started but phase II results do not guarantee phase III success, approval, or long‑term safety. The Nature article is a secondary review of the cited trial reports.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
